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Rationale: The relationship between pulmonary artery size with underlying pulmonary hyper-
tension and mortality remains to be determined in COPD. We sought to evaluate the relation-
ships in a cohort of patients with advanced COPD.
Methods: A retrospective study of advanced COPD patients evaluated between 1998 and 2012
was conducted at a tertiary care center. Patients with chest computed tomography images and
right heart catheterizations formed the study cohort. The diameters of the pulmonary artery
and ascending aorta were measured by independent observers and compared to pulmonary ar-
tery pressures. Intermediate-term mortality was evaluated for the 24-month period subse-
quent to the respective studies. Cox proportional hazards model was used to determine
independent effects of variables on survival.ive pulmonary disease; PA:A, pulmonary to aortic artery diameter ratio; PH, pulmonary hypertension;
econd; DLco, diffusing capacity for carbon monoxide; CT, computed tomography; mPAP, mean pul-
heart catheterization; sPAP, systolic pulmonary artery pressure; dPAP, diastolic pulmonary artery
edge pressure; HR, hazard ratio; PAD, pulmonary artery diameter; AUC, area under the ROC curve.
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Pulmonary artery size as a predictor of PH and outcomes in patients with COPD 1627Results: There were 65 subjects identified, of whom 38 (58%) had pulmonary hypertension. Pa-
tients with and without pulmonary hypertension had mean pulmonary artery diameters of
34.4 mm and 29.1 mm, respectively (p Z 0.0003). The mean PA:A ratio for those with and
without pulmonary hypertension was 1.05 and 0.87, respectively (pZ 0.0003). The PA:A ratio
was an independent predictor of mortality with a reduced survival in those with a PA:A >1
(p Z 0.008).
Conclusions: The PA:A ratio is associated with underlying pulmonary hypertension in patients
with COPD and is an independent predictor of mortality. This readily available measurement
may be a valuable non-invasive screening tool for underlying pulmonary hypertension in COPD
patients and appears to impart important independent prognostic information.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is now the
third leading cause of death in the United States [1]. Known
risk factors for mortality include the forced expiratory vol-
ume in 1 second (FEV1), arterial blood gas values and age [2].
Recent studies have also demonstrated that smoking status,
anemia, and reductions in lean body mass may be associated
with reduced survival in this population [2e4]. Despite the
ready availability of these parameters, the outcomes of
COPD patients are still notoriously difficult to predict.
Pulmonary hypertension (PH) frequently complicates
the course of patients with advanced COPD [5]. The
presence of PH may be important to identify, as these
patients tend to have greater oxygen needs, reduced
functional ability, an apparent increased risk of acute
exacerbations and an increased risk of mortality [5e7].
Indeed, areas on the composite BODE index performs well
as a prognostic indicator could be attributable to its latter
two components which may be affected by the presence of
underlying PH.
It is difficult to predict the presence of underlying PH
based on lung function alone given the lack of a clear rela-
tionship between the severity of PH and spirometric indices.
Screening tools that have been touted include serologic
markers (brain natriuretic peptide/N-terminal pro b-type
natriuretic peptide), the six-minute walk test and a reduced
single-breath diffusing capacity for carbon monoxide (DLco)
[8e11]. The most commonly used screening tool for PH is
echocardiography. However, this is inherently inaccurate,
especially in patientswithCOPD,where severehyperinflation
often hinders the attainment of an adequate window [12].
Prior studies suggest a relationship between the pul-
monary arterial (PA) diameter and PH in patients with
various underlying disorders [13,14]. There is data to sug-
gest a relationship between PA size and acute exacerba-
tions of COPD [13,15]. A recent smaller retrospective study
presented data that suggests a correlation between
pulmonary artery size on computed tomography (CT) im-
ages and pulmonary artery pressures on right heart cathe-
terization (RHC) [16]. However, the prognostic value of PA
size remains unclear and uninvestigated in patients with
COPD. We therefore sought to validate the relationship
between PA:A ratio and PA diameter size on CT imaging
with the mean pulmonary artery pressure (mPAP) measuredby RHC in a cohort of COPD patients. In addition, we also
sought to evaluate the prognostic ability of these readily
available CT measurements in comparison to other more
commonly established COPD prognostic indicators,
including the FEV1 and mPAP.
Methods
Patients with a primary diagnosis of COPD evaluated in an
Advanced Lung Disease clinic for potential lung trans-
plantation or volume reduction surgery between January
1998 and December 2012 were identified. Only those with
available chest CT scans and contemporaneous RHC data
were eligible to be included in this study. For those with
PH, a comprehensive evaluation was undertaken to exclude
other potential contributors to their PH.
The PA:A ratio was calculated from the diameters of the
PA and ascending aorta measured by five of the authors who
independently and in a blinded fashion read the CT scans of
all the patients. The PA segment was measured at the
bifurcationwith the greatest diameter of the aortameasured
at the same level [15]. These were compared to the mPAP,
systolic pulmonary artery pressure (sPAP), and the diastolic
pulmonary artery pressure (dPAP), as measured on RHC. A
subgroup analysis, excluding those with ascending thoracic
aorta dilation/aneurysm and pulmonary capillary wedge
pressures (PCWP) > 15 mmHg on RHC [World Health Organi-
zation (WHO) Group II PH], was performed [17]. The defini-
tion of ascending thoracic aorta aneurysm/dilation
accounted for the effects of age and gender [18].
Transplant-free survival based on the PA segment size,
the PA:A ratio, the mPAP and the FEV1 were evaluated over
the 2-year period subsequent to the respective studies.
Time zero for each patient from which survival was calcu-
lated was the date of the CT scan, the date of the RHC and
date of the pulmonary function tests (PFTs), respectively.
Patients were censored at the time of death or lung
transplantation. The study was approved by the Inova
institutional review board (IRB00002273).
Statistics
All demographic and PFT data are presented as means if
continuous, or as frequencies if categorical with standard
1628 S. Shin et al.deviations (SD). Parametric statistics were used where
the data was confirmed to have a normal distribution. The
median values of PA diameter and PA:A ratio measured by
five authors were used. The intraclass correlation coeffi-
cient was used to assess the level of agreement among
readers for the continuous variables of PA diameter and
PA:A ratio [19,20]. Pearson’s correlation coefficient was
utilized to compare pulmonary diameter and PA:A ratio to
the pulmonary pressures. Comparisons of measurements
between two groups were performed with unpaired t-tests.
A receiver operating characteristic (ROC) analysis was
completed to assess the performance characteristics of the
PA:A ratio and PA diameter for the detection of PH. Only
all-cause mortality was considered in this study.
Transplant-free survival analyses were performed with
KaplaneMeier curves and log-rank testing. A multivariable
Cox proportional hazards analysis was performed to assess
the association between PA:A ratio and death or trans-
plantation by controlling for potential confounding factors
including patient age, BMI (body mass index) and FEV1%.
Hazard ratios (HR) were attained from the Cox model. All
calculations were performed using SAS software (v9.2, SAS
Institute; Cary, NC) and IBM SPSS software (v20.0, IBM;
Armonk, NY).Results
We initially identified 94 COPD patients who were evalu-
ated over the 14-year period in whom PFTs, chest CT im-
ages and RHC data were available. There were 65 patients
in whom the CT scan to RHC time interval was less than 3
months apart that formed the final study population. The
demographics and lung function of the group are shown in
Table 1. The patients were divided into two groups based
on those with (mPAP  25 mmHg) and without PHTable 1 Patient characteristics stratified by the presence
of pulmonary hypertension.
Demographic
and PFTa variables
mPAP
<25 mmHg
(N Z 27)
MPAP
25 mmHg
(N Z 38)
p Value
Age (years) 57 61 0.02
BMI (kg/m2) 25 28 0.04
Female gender (n) 15 17 0.40
FVC (% predicted) 56 63 0.27
FEV1 (% predicted) 24 37 0.01
FEV1/FVC (%) 33 47 <0.01
TLC (% predicted) 126 111 0.19
DLco (% predicted) 36 30 0.05
Data presented as means. Significance tests for comparisons
between groups based on 2-sample independent t-test for
continuous patient characteristics and Pearson’s chi-square test
for categorical patient characteristics.
Abbreviations: PFT Z pulmonary function test; mPAP Z mean
pulmonary artery pressure; BMI Z body mass index;
FVC Z forced vital capacity; FEV1 Z forced expiratory volume
in 1 second; TLC Z total lung capacity; DLco Z diffusing ca-
pacity of the lung for carbon monoxide.
a PFT missing patient data: FEV1 (n Z 4); FVC (n Z 4); TLC
(n Z 17); DLco (n Z 11).(mPAP < 25 mmHg). For the group with PH, an evaluation
for other causes revealed one patient with obstructive
sleep apnea, none with systolic heart failure, and 17 pa-
tients in whom the PCWP was >15 mmHg on RHC.
The baseline characteristics between the two subgroups
were not statistically significant with the exception of the
age, BMI, FEV1 and DLco. Specifically, the FEV1 was higher
in the PH group, while the DLco was lower. The median
time interval between the chest CT and RHC was 0.7
months (range: 0.03e2.83 months; mean: 0.89 months).
The overall mean PA diameter and PA:A ratio were
34.0 mm (95% CI [32.6e35.5]) and 1.02 (95% CI
[0.97e1.06]), respectively. The intraclass correlation co-
efficient for both PA:A ratio and PA diameter amongst the
five readers showed excellent agreement with values of
0.94 (95% CI [0.91e0.96], p < 0.01) and 0.93 (95% CI
[0.90e0.96], p < 0.01), respectively.
The mean sPAP, dPAP and mPAP of the cohort were
46 mmHg, 20 mmHg and 31 mmHg, respectively. As shown
in Table 2, patients with mPAP <25 mmHg (n Z 27) had a
mean PA diameter of 29.1 mm compared to 34.4 mm in
those with mPAP 25 mmHg (n Z 38), (p Z 0.0003). The
mean PA:A ratio for patients with mPAP <25 mmHg was
0.87 versus 1.05 in those with mPAP 25 mmHg
(p Z 0.0003). The mean PA:A ratio and PA diameter based
on PH severity is shown in Table 3. There was a significant
correlation between the pulmonary pressures measured on
RHC and PA size on CT scans. In this regard, the mPAP and
PA:A ratio showed the best correlation with a coefficient
(R) of 0.60 (p < 0.001). The correlation between the sPAP
and dPAP with the pulmonary size was weaker with values
of 0.53, 0.55 for the PA:A ratio and 0.55, 0.54 for the PA
diameter, respectively (both, p < 0.001).
Fig. 1 demonstrates the area under the ROC curves
(AUC) of PA diameter and PA:A ratio for the detection of PH
as 0.78 (CI 0.66e0.90, p < 0.001) and 0.79 (CI 0.68e0.90,
p < 0.001), respectively. The sensitivity and specificity for
PH detection using a PA:A ratio >1 was 50% and 93%,
respectively. The negative predictive value and positive
predictive value of this cut point were 57% and 90%,
respectively.
Transplant-free survival analyses over 24 months strati-
fied by PA:A ratio, PA diameter, mPAP and FEV1 are shown
in Fig. 2(A)e(D). Those with PA:A ratio >1 had worse sur-
vival compared to those with PA:A 1 (Fig. 2(A),
p Z 0.008), while the PA diameter trended towards a sur-
vival difference (Fig. 2(B), p Z 0.02). Subjects with mPAP
25 mmHg also had reduced survivals compared to those
without PH on RHC (Fig. 2(C), p Z 0.009). The survival
analysis based on the median FEV1 demonstrated no sta-
tistical significance (Fig. 2(D), p Z 0.32). Furthermore,
survival decreased as the mPAP increased (Fig. 3). The
subgroup analysis of patients with both a normal aortic size
and a PCWP 15 mmHg (N Z 49) showed similar trends in
survival as depicted in Fig. 4(A)e(D).
The Cox proportional hazards model (Table 4) demon-
strated that the PA:A ratio >1 was the only significant
predictor of transplant-free survival in both unadjusted and
adjusted analyses (HR Z 4.88; 95% CI [1.75e13.6],
p Z 0.002) and (HR Z 5.05; 95% CI [1.63e15.6],
p Z 0.005), respectively. The other variables included in
the model (age, BMI, FEV1) were not statistically significant
Table 2 Pulmonary artery characteristics stratified by the presence of pulmonary hypertension.
Group Mean
mPAP
(mmHg)
(95% CI) Mean
ascending
aorta (mm)
(95% CI) Mean PA
diameter
(mm)
(95% CI) Mean
PA:A ratio
(95% CI)
mPAP < 25 mmHg
(N Z 27)
20.6 (19.5e21.5) 33.4 (32.0e34.7) 29.1 (27.5e30.8) 0.87 (0.83e0.91)
mPAP  25 mmHg
(N Z 38)
37.8 (33.61e41.91) 33.3 (32.0e34.6) 34.4 (32.4e36.3) 1.05 (0.98e1.12)
p Value <0.0001 0.93 0.0003 0.0003
Data presented as means with 95% confidence intervals. Significance tests for comparisons between groups based on 2-sample t-test.
Abbreviations: mPAP Z mean pulmonary artery pressure; CI Z confidence interval; PA Z pulmonary artery; PA:A ratio Z pulmonary
artery to aorta diameter ratio.
Pulmonary artery size as a predictor of PH and outcomes in patients with COPD 1629predictors of mortality. The PA diameter and mPAP were
not included in the Cox analysis due to their colinearity
with the PA:A ratio with correlation coefficients of 0.80 and
0.60, respectively.
Discussion
In this study we demonstrate that a PA:A ratio >1 is an
independent predictor of intermediate-term transplant-
free survival in COPD patients and also confirm the corre-
lation between PA:A ratio and mPAP. Prior studies have
demonstrated that the PA:A ratio measured on CT does
correlate with PA pressures, but the sample size of COPD
patients studied was smaller than in our current study
[13,16,21,22]. A link between PA:A ratio >1 and the risk for
acute exacerbations of COPD has previously been described
[15]. However, to our knowledge, our study is the first to
establish an association between the PA:A ratio and mor-
tality in COPD.
The accurate estimation of prognosis in COPD is impor-
tant for many reasons. Not only does it afford clinicians
information to appropriately counsel patients and their
families regarding healthcare and end-of-life decisions, but
it also enables the optimal timing of lung transplantation
with implications for both individual patients and optimal
lung resource utilization. Unfortunately, prognostication in
COPD remains an imperfect science. Traditionally, prog-
nosis was thought to be primarily based on the severity of
airflow obstruction as measured by the FEV1. However this
physiologic measurement fails to take into consideration
the systemic effects of COPD and the variable outcomes
associated with discrete phenotypes.
Currently, the BODE index, (which incorporates body
mass index, the degree of airflow obstruction,Table 3 Pulmonary artery size stratified by mean pul-
monary artery pressure.
mPAP
(mmHg)
PH severity N (%) Mean
PA:A ratio
Mean PA
diameter (mm)
24 Normal 27 (42%) 0.87 29.1
25e34 PH 21 (32%) 0.94 31.5
35 Severe PH 17 (26%) 1.18 37.9
Abbreviations: mPAP Z mean pulmonary artery pressure;
PH Z pulmonary hypertension; PA:A Z pulmonary artery to
aorta diameter ratio; PA Z pulmonary artery.breathlessness as measured by the modified Medical
Research Council dyspnea scale and functional status on
six-minute walk test), is the most commonly used prog-
nostic tool [23]. Although this has served clinicians well,
ongoing efforts to further refine prognostication in COPD
remain necessary. In this regard, the PA:A ratio may
represent a valuable ancillary prognostic indicator. Given
the positive results of the recent National Lung Screening
Trial and subsequent endorsement of low dose CT screening
for lung cancer in high-risk patients by a number of orga-
nizations, it is likely that many more COPD patients will
have CT data available [24,25]. The measurements
described appear to be practical for clinicians to perform
without the use of intravascular contrast material or special
software. Our study is also unique in that we have also
demonstrated excellent intraclass correlation among
readers with a broad range of clinical experience including
a medical resident, a pulmonary fellow, two pulmonologists
and a radiologist. This further attests to the value and easeFigure 1 ROC curves for pulmonary artery diameter and
pulmonary artery to aorta diameter ratio for the detection of
PH in patients with severe COPD. Abbreviations:
PA:AZ pulmonary artery to aorta diameter ratio, AUCZ area
under the ROC curve.
Figure 2 Transplant-free survival of the COPD cohort based on (A) PA:A ratio > 1 (B) median PA diameter (C) mPAP (<25 mmHg,
25 mmHg) (D) median FEV1 for the 24-month period from the date of each respective study.
1630 S. Shin et al.of implementing the measurement of this ratio on a routine
basis. The PA:A ratio also demonstrated good positive pre-
dictive value for the presence of PH and may serve as a
screen for patients who might benefit from information
derived from a right heart catheterization.
There are several possible explanations for the observed
increase in mortality with an increasing PA:A ratio. It is
possible that an increase in PA:A ratio serves as a surrogate
for underlying PH, which may be responsible for the
observed increase in mortality. PH is well recognized as
being associated with increased mortality in COPD [26].
Indeed, our survival analysis based on PH severity did
demonstrate increasing mortality with sequentially higher
PA pressures, as has been demonstrated previously [27].
However, the fact that PH was not associated with mor-
tality in our Cox hazards model raises the possibility that
other factors may affect the PA diameter. For example, we
cannot rule out that the previously demonstrated predi-
lection to acute exacerbations of COPD with an increasedFigure 3 Transplant-free survival of the COPD cohort based
on mPAP gradation (<25 mmHg; 25e34 mmHg; 35 mmHg) for
the 24-month period from the date of the RHC.PA:A ratio may have contributed to our demonstration of
worsened outcomes [15]. Another consideration is that
some of the PH observed is due to left-sided heart disease
[28]. However, our subgroup analysis those without aortic
dilation and elevated PCWPs showed similar relationships
between the PA:A ratio and PA pressures on survival. Other
conditions associated with PH such as obstructive sleep
apnea and venous thromboembolism may have also
impacted mortality. Also, the parenchymal lung disease
itself may play a role influencing the vascular dimensions.
However, it is doubtful that mechanical effects of the hy-
perinflated lungs would result in compression of the aorta.
Similarly, it is unlikely that the surrounding emphysematous
lung tissue would enable radial expansion of the PA
segment.
Our study has several limitations. The study population
consists of severe COPD patients referred to a single ter-
tiary institution limiting the applicability of our findings to
broader groups of COPD patients. We limited our analysis to
only those patients with CT and RHCs within 3 months but
there was still a slight time interval between the CT and
RHC in some of the patients. While this slight time lag might
have impacted our analysis of the relationship between PA
pressure and CT measurements, it did not impact our sur-
vival analyses since these were all calculated from the date
of the respective studies. We arbitrarily chose two years of
follow-up for our mortality analysis, since we felt that
other interceding events might have an undue influence on
outcomes over a longer period. We were limited in our
ability to adjust for further variables (i.e. mPAP and DLco)
due to colinearity and our small sample size; specifically,
inclusion of additional variables would have compromised
the overall strength of the Cox proportional hazards model.
The narrow range of FEV1’s in our patient cohort together
with the small sample size may explain this probable type 2
error where FEV1 was not associated with mortality.
Figure 4 Transplant-free survival analysis of COPD subgroup without aortic dilation/aneurysm or evidence of pulmonary venous
hypertension as defined by PCWP >15 mmHg (N Z 49) based on: (A) PA:A ratio > 1; (B) median PA diameter; (C) mPAP gradation
(<25 mmHg; 25e34 mmHg; 35 mmHg); (D) median FEV1. KaplaneMeier survival estimates over 24 months.
Table 4 Unadjusted and adjusted hazard ratios for death or transplant (N Z 65).
Unadjusted analysis (N Z 65) Adjusted analysis (N Z 61)
Hazard ratio (95% CI) p Value Hazard ratio (95% CI) p Value
Age 1.05 0.97e1.13 0.25 0.99 0.91e1.09 0.92
BMI (kg/m2) 0.99 0.91e1.08 0.83 0.99 0.91e1.06 0.70
FEV1 (% predicted)
a 1.02 0.99e1.05 0.06 1.02 0.98e1.05 0.40
PA:A ratio >1 4.88 1.75e13.6 0.002 5.05 1.63e15.6 0.005
Based on Cox proportional hazards regression model adjusted for age, BMI, FEV1 and PA:A ratio >1.
Abbreviations: CI Z confidence interval; PA:A Z pulmonary artery to aorta diameter ratio; BMI Z body mass index; mPAP Z mean
pulmonary artery pressure; FEV1 Z forced expiratory volume in 1 second; DLco Z diffusing capacity for carbon monoxide.
a 4 patients had missing FEV1 data that resulted N Z 61 for the unadjusted FEV1 and overall adjusted analysis.
Pulmonary artery size as a predictor of PH and outcomes in patients with COPD 1631In conclusion, the PA:A ratio is an easily obtainable
measurement that can be performed on routine chest CT
scans. The PA:A ratio correlates with the presence of PH
and a PA:A ratio >1 is independently associated with
increased mortality in COPD patients. Our study provides an
important step toward improved prognostication in COPD.
Ideally, the association between PA:A ratio and COPD
mortality should be confirmed in future larger, multi-center
studies including a wider spectrum of disease severity.
Another aspect for future research is whether the addition
of the PA:A ratio to known prognostic tools such as the
BODE index might improve the accuracy of this or other
predictive models.
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